Cargando…
Lung function and microbiota diversity in cystic fibrosis
BACKGROUND: Chronic infection and concomitant airway inflammation is the leading cause of morbidity and mortality for people living with cystic fibrosis (CF). Although chronic infection in CF is undeniably polymicrobial, involving a lung microbiota, infection surveillance and control approaches rema...
Autores principales: | , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7114784/ https://www.ncbi.nlm.nih.gov/pubmed/32238195 http://dx.doi.org/10.1186/s40168-020-00810-3 |
_version_ | 1783513960875556864 |
---|---|
author | Cuthbertson, Leah Walker, Alan W. Oliver, Anna E. Rogers, Geraint B. Rivett, Damian W. Hampton, Thomas H. Ashare, Alix Elborn, J. Stuart De Soyza, Anthony Carroll, Mary P. Hoffman, Lucas R. Lanyon, Clare Moskowitz, Samuel M. O’Toole, George A. Parkhill, Julian Planet, Paul J. Teneback, Charlotte C. Tunney, Michael M. Zuckerman, Jonathan B. Bruce, Kenneth D. van der Gast, Christopher J. |
author_facet | Cuthbertson, Leah Walker, Alan W. Oliver, Anna E. Rogers, Geraint B. Rivett, Damian W. Hampton, Thomas H. Ashare, Alix Elborn, J. Stuart De Soyza, Anthony Carroll, Mary P. Hoffman, Lucas R. Lanyon, Clare Moskowitz, Samuel M. O’Toole, George A. Parkhill, Julian Planet, Paul J. Teneback, Charlotte C. Tunney, Michael M. Zuckerman, Jonathan B. Bruce, Kenneth D. van der Gast, Christopher J. |
author_sort | Cuthbertson, Leah |
collection | PubMed |
description | BACKGROUND: Chronic infection and concomitant airway inflammation is the leading cause of morbidity and mortality for people living with cystic fibrosis (CF). Although chronic infection in CF is undeniably polymicrobial, involving a lung microbiota, infection surveillance and control approaches remain underpinned by classical aerobic culture-based microbiology. How to use microbiomics to direct clinical management of CF airway infections remains a crucial challenge. A pivotal step towards leveraging microbiome approaches in CF clinical care is to understand the ecology of the CF lung microbiome and identify ecological patterns of CF microbiota across a wide spectrum of lung disease. Assessing sputum samples from 299 patients attending 13 CF centres in Europe and the USA, we determined whether the emerging relationship of decreasing microbiota diversity with worsening lung function could be considered a generalised pattern of CF lung microbiota and explored its potential as an informative indicator of lung disease state in CF. RESULTS: We tested and found decreasing microbiota diversity with a reduction in lung function to be a significant ecological pattern. Moreover, the loss of diversity was accompanied by an increase in microbiota dominance. Subsequently, we stratified patients into lung disease categories of increasing disease severity to further investigate relationships between microbiota characteristics and lung function, and the factors contributing to microbiota variance. Core taxa group composition became highly conserved within the severe disease category, while the rarer satellite taxa underpinned the high variability observed in the microbiota diversity. Further, the lung microbiota of individual patient were increasingly dominated by recognised CF pathogens as lung function decreased. Conversely, other bacteria, especially obligate anaerobes, increasingly dominated in those with better lung function. Ordination analyses revealed lung function and antibiotics to be main explanators of compositional variance in the microbiota and the core and satellite taxa. Biogeography was found to influence acquisition of the rarer satellite taxa. CONCLUSIONS: Our findings demonstrate that microbiota diversity and dominance, as well as the identity of the dominant bacterial species, in combination with measures of lung function, can be used as informative indicators of disease state in CF. |
format | Online Article Text |
id | pubmed-7114784 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-71147842020-04-07 Lung function and microbiota diversity in cystic fibrosis Cuthbertson, Leah Walker, Alan W. Oliver, Anna E. Rogers, Geraint B. Rivett, Damian W. Hampton, Thomas H. Ashare, Alix Elborn, J. Stuart De Soyza, Anthony Carroll, Mary P. Hoffman, Lucas R. Lanyon, Clare Moskowitz, Samuel M. O’Toole, George A. Parkhill, Julian Planet, Paul J. Teneback, Charlotte C. Tunney, Michael M. Zuckerman, Jonathan B. Bruce, Kenneth D. van der Gast, Christopher J. Microbiome Research BACKGROUND: Chronic infection and concomitant airway inflammation is the leading cause of morbidity and mortality for people living with cystic fibrosis (CF). Although chronic infection in CF is undeniably polymicrobial, involving a lung microbiota, infection surveillance and control approaches remain underpinned by classical aerobic culture-based microbiology. How to use microbiomics to direct clinical management of CF airway infections remains a crucial challenge. A pivotal step towards leveraging microbiome approaches in CF clinical care is to understand the ecology of the CF lung microbiome and identify ecological patterns of CF microbiota across a wide spectrum of lung disease. Assessing sputum samples from 299 patients attending 13 CF centres in Europe and the USA, we determined whether the emerging relationship of decreasing microbiota diversity with worsening lung function could be considered a generalised pattern of CF lung microbiota and explored its potential as an informative indicator of lung disease state in CF. RESULTS: We tested and found decreasing microbiota diversity with a reduction in lung function to be a significant ecological pattern. Moreover, the loss of diversity was accompanied by an increase in microbiota dominance. Subsequently, we stratified patients into lung disease categories of increasing disease severity to further investigate relationships between microbiota characteristics and lung function, and the factors contributing to microbiota variance. Core taxa group composition became highly conserved within the severe disease category, while the rarer satellite taxa underpinned the high variability observed in the microbiota diversity. Further, the lung microbiota of individual patient were increasingly dominated by recognised CF pathogens as lung function decreased. Conversely, other bacteria, especially obligate anaerobes, increasingly dominated in those with better lung function. Ordination analyses revealed lung function and antibiotics to be main explanators of compositional variance in the microbiota and the core and satellite taxa. Biogeography was found to influence acquisition of the rarer satellite taxa. CONCLUSIONS: Our findings demonstrate that microbiota diversity and dominance, as well as the identity of the dominant bacterial species, in combination with measures of lung function, can be used as informative indicators of disease state in CF. BioMed Central 2020-04-02 /pmc/articles/PMC7114784/ /pubmed/32238195 http://dx.doi.org/10.1186/s40168-020-00810-3 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Cuthbertson, Leah Walker, Alan W. Oliver, Anna E. Rogers, Geraint B. Rivett, Damian W. Hampton, Thomas H. Ashare, Alix Elborn, J. Stuart De Soyza, Anthony Carroll, Mary P. Hoffman, Lucas R. Lanyon, Clare Moskowitz, Samuel M. O’Toole, George A. Parkhill, Julian Planet, Paul J. Teneback, Charlotte C. Tunney, Michael M. Zuckerman, Jonathan B. Bruce, Kenneth D. van der Gast, Christopher J. Lung function and microbiota diversity in cystic fibrosis |
title | Lung function and microbiota diversity in cystic fibrosis |
title_full | Lung function and microbiota diversity in cystic fibrosis |
title_fullStr | Lung function and microbiota diversity in cystic fibrosis |
title_full_unstemmed | Lung function and microbiota diversity in cystic fibrosis |
title_short | Lung function and microbiota diversity in cystic fibrosis |
title_sort | lung function and microbiota diversity in cystic fibrosis |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7114784/ https://www.ncbi.nlm.nih.gov/pubmed/32238195 http://dx.doi.org/10.1186/s40168-020-00810-3 |
work_keys_str_mv | AT cuthbertsonleah lungfunctionandmicrobiotadiversityincysticfibrosis AT walkeralanw lungfunctionandmicrobiotadiversityincysticfibrosis AT oliverannae lungfunctionandmicrobiotadiversityincysticfibrosis AT rogersgeraintb lungfunctionandmicrobiotadiversityincysticfibrosis AT rivettdamianw lungfunctionandmicrobiotadiversityincysticfibrosis AT hamptonthomash lungfunctionandmicrobiotadiversityincysticfibrosis AT asharealix lungfunctionandmicrobiotadiversityincysticfibrosis AT elbornjstuart lungfunctionandmicrobiotadiversityincysticfibrosis AT desoyzaanthony lungfunctionandmicrobiotadiversityincysticfibrosis AT carrollmaryp lungfunctionandmicrobiotadiversityincysticfibrosis AT hoffmanlucasr lungfunctionandmicrobiotadiversityincysticfibrosis AT lanyonclare lungfunctionandmicrobiotadiversityincysticfibrosis AT moskowitzsamuelm lungfunctionandmicrobiotadiversityincysticfibrosis AT otoolegeorgea lungfunctionandmicrobiotadiversityincysticfibrosis AT parkhilljulian lungfunctionandmicrobiotadiversityincysticfibrosis AT planetpaulj lungfunctionandmicrobiotadiversityincysticfibrosis AT tenebackcharlottec lungfunctionandmicrobiotadiversityincysticfibrosis AT tunneymichaelm lungfunctionandmicrobiotadiversityincysticfibrosis AT zuckermanjonathanb lungfunctionandmicrobiotadiversityincysticfibrosis AT brucekennethd lungfunctionandmicrobiotadiversityincysticfibrosis AT vandergastchristopherj lungfunctionandmicrobiotadiversityincysticfibrosis |